We previously reported that targeting nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme that catalyzes NAD+ synthesis from nicotinamide (NAM), is a promising approach to eliminate blood tumor cells that are highly dependent on NAD+, such as B-chronic lymphocytic leukemia (B-CLL), lymphomas, MM, and acute myeloid leukemia (AML) [11,12,13,14]. This evidence concerns the gene NAMPT and Miyoshi myopathy.